Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Insulet Corporation

PODD

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Last trade $146.72
Day change +$1.43 (+0.98%)
Day range $141.56 – $148.57
Volume 775,978
Market cap $10.08B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.08B
Price / earnings
23.5×
Price / book
6.38×
Price / sales
3.16×
EV / sales
3.28×
EV / EBITDA
15.08×

Profitability

Earnings per share
$6.18
Return on assets
12.56%
Return on equity
27.15%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.61×
Current ratio
2.51×
Quick ratio
1.83×
Cash ratio
0.72×

Cash flow

Price / cash flow
19.8×
Price / free cash flow
39.65×
Free cash flow
$254.2M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PODD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$842M$801.7M$761.7M$783.8M$706.3M$649.1M$569M$597.5M
Cost of revenue$209.9M$239.1M$232.7M$215.2M$196.2M$196.9M$159.9M$166.6M
Gross profit$632.1M$562.6M$529M$568.6M$510.1M$452.2M$409.1M$430.9M
Selling, general and administrative$350.7M$344.8M$317.2M$331.4M$315.2M$257.7M$260.7M$261M
Research and development$91.6M$88.1M$89.7M$90.9M$77.2M$73.4M$59.6M$60.6M
Total operating expenses$442.3M$432.9M$406.9M$422.3M$392.4M$331.1M$320.3M$321.6M
Operating income$189.8M$129.7M$122.1M$146.3M$117.7M$121.1M$88.8M$109.3M
Interest expense-$16.2M-$13.5M-$14.7M-$14.9M-$15.6M-$19.6M-$9.2M-$8.6M
Income before taxes$177.2M$118.7M$113M$140.2M$122.8M$28.4M$48.2M$111.4M
Income taxes$36.1M$23.7M$21.9M$38.6M$35.2M$5.9M$12.7M$10.7M
Net income$141.1M$95M$91.1M$101.6M$87.6M$22.5M$35.5M$100.7M
Net income attributable to common shareholders$141.1M$95M$91.1M$101.6M$87.6M$22.5M$35.4M$100.7M
EBITDA$218M$156.4M$148.3M$170.7M$139.7M$143.4M$110.5M$130.8M
Basic earnings per share$2.03$1.37$1.30$1.44$1.24$0.32$0.50$1.44
Diluted earnings per share$2.03$1.37$1.30$1.41$1.24$0.32$0.50$1.36

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott reported strong mid-to-high-teens EP sales growth globally and over 20% in the U.S., driven by accelerating Volt PFA catheter adoption following its August launch. The company received FDA approval for TactiFlex Duo and CE Mark for Amulet 360, expanding treatment options. However, LAA market weakness is creating headwinds as customers delay purchases awaiting the new Amulet 360 device. Abbott expects Japan's Q4 Volt launch to provide growth momentum.

Zacks Investment Research

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Insulet Corporation (PODD), a manufacturer of continuous insulin delivery systems, has been highlighted as a top growth investment opportunity. The company holds a Zacks Rank #2 (Buy) rating with a VGM Score of B and Growth Style Score of B, forecasting 36% year-over-year earnings growth for the current fiscal year. Eight analysts revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $6.76 per share for fiscal 2026.

Zacks Investment Research

Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Insulet (PODD) is recommended as a growth stock with a Zacks Growth Score of B and Zacks Rank #2 (Buy). The company demonstrates strong fundamentals including 35.3% projected EPS growth (vs. 9.1% industry average), 42.9% year-over-year cash flow growth (vs. -2.1% industry average), and positive earnings estimate revisions of 3.7% over the past month.

Zacks Investment Research

Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth

Insulet is expected to report Q3 2026 earnings on November 4 with consensus EPS of $1.59 (+28.2% YoY) and revenues of $833.3 million (+18% YoY). However, recent analyst revisions suggest bearish sentiment with a negative Earnings ESP of -1.86%, making an earnings beat unlikely despite the company's strong historical track record of beating estimates.

GlobeNewswire Inc.

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale

The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.